• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Novartis

Novartis

Novartis AG ADR NVS

Last Price$81.22Day Change (%)0.42%
Open Price$81.21Day Change ($)0.34
Day Range80.64–81.3952-Week Range69.90–95.11

As of Wed 9/28/2016 6:16:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Global Urological Cancer Market Forecast to 2022 - Key Players are Novartis , Pfizer & AstraZeneca - Research and Markets

    Global Urological Cancer Market Forecast to 2022 - Key Players are Novartis , Pfizer & AstraZeneca - Research and Markets

  2. Influenza Market 2015-2020: Global Industry Perspective, Comprehensive Analysis and Forecasts Featuring AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis , Sanofi-Pasteur - Research and Markets

    Influenza Market 2015-2020: Global Industry Perspective, Comprehensive Analysis and Forecasts Featuring AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis , Sanofi-Pasteur - Research and Markets

  3. FDA Approves Novartis's Biosimilar to Amgen's Enbrel

    FDA Approves Novartis's Biosimilar to Amgen's Enbrel

  4. FDA Approves Novartis's Biosimilar to Amgen's Enbrel

    FDA Approves Novartis's Biosimilar to Amgen's Enbrel

  5. Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets

    Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets

  6. GlaxoSmithKline Names Emma Walmsley as Next Chief Executive -- 3rd Update

    GlaxoSmithKline Names Emma Walmsley as Next Chief Executive -- 3rd Update

  7. GlaxoSmithKline Names Emma Walmsley as Next Chief Executive -- Update

    GlaxoSmithKline Names Emma Walmsley as Next Chief Executive -- Update

  8. Polycythemia Vera Pipeline Report 2016 - Review of 12 Companies & 15 Molecules - Research and Markets

    Polycythemia Vera Pipeline Report 2016 - Review of 12 Companies & 15 Molecules - Research and Markets

  9. UPDATE: Allergan is paying a stunning 500% premium to buy a clinical-stage biotech

    UPDATE: Allergan is paying a stunning 500% premium to buy a clinical-stage biotech

  10. Medullary Thyroid Cancer Pipeline Review, H2 2016 - Companies & Molecules by Phase III, Phase II & Pre-Clinical Stage - Research and Markets

    Medullary Thyroid Cancer Pipeline Review, H2 2016 - Companies & Molecules by Phase III, Phase II & Pre-Clinical Stage - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.